ClinicalTrials.gg
RecruitingNCT06384456TRADRUpdated May 4, 2026

Topical TRanexamic Acid vs. Placebo on Acute Postoperative Pain Following DRF Fixation

A Phase 4 interventional study of Topical TRanexamic Acid and Placebo in Distal Radius Fractures, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University Health Network, Toronto · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Wrist Fractures with a site in Canada — 4 open to participants now, 4 under way, none of them phase 3. Wrist Fractures · Canada.

Planned enrollment
9th of 19
90 · median 74
Started
2025
the only one that year
Phase 4
4 of 22
1 open now
Registered
21st of 22
by date

Among the 22 studies in Wrist Fractures with a site in Canada, this one is the 9th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 4, and was the 21st registered.

Wrist Fractures

331 studies on the registry are indexed under Wrist Fractures; 71 are open to participants now.

Browse Wrist Fractures studies →

Open to participants now

4 of the 22 studies in Wrist Fractures with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 41 Wrist Fractures studies recruiting now, 20 (49%) set no upper age limit and 13 (32%) stop at 75 or younger; 7 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Wrist Fractures with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study is to find out whether the use of topical tranexamic acid (TXA) into the surgical wound will result in less post-operative pain, less pain killer use, and better post-operative use of the wrist in people undergoing surgery for a wrist fracture compared to not using topical TXA (placebo).

03

Conditions studied

  • Distal Radius Fractures

Keywords

  • Distal Radius Fractures
  • acute pain
  • Topical tranexamic acid
  • Open Reduction and Internal FIxation
  • Placebo
  • Randomized Control Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing open reduction internal fixation (Volar approach) for operative management of a distal radius fracture;
  • Aged 18 or older;
  • Provision of ;
  • Cognitive ability and English-language skills required to complete outcome measures.

Exclusion criteria

Exclusion Criteria:

  • Revision surgery or any additional operative management of ipsilateral wrist injury
  • Distal radius fracture treated with a dorsal approach
  • Known history of lymphedema or lymph node dissection in the operative extremity
  • Known chronic pain conditions, fibromyalgia, or polymyalgia rheumatic
  • Current user of opioids and/or on chronic opioids use
  • Known allergic reaction to TXA
  • Anticoagulant use not stopped in time for surgery as per thrombosis Canada guidelines (i.e. warfarin, acetylsalicylic acid, direct oral anticoagulants, etc.)
  • Previous thrombotic stroke or thromboembolic disorders (i.e. known previous DVT, PE, or clotting disorders)
  • Current pregnancy or breastfeeding
  • Previous neurologic injury causing paralysis of affected shoulder/arm
  • Severe cardio-respiratory disease (i.e. ASA Grade IV or higher).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Topical TRanexamic Acid

    10mL of 100mg/mL TXA in addition to the standard care

    Drug: Topical TRanexamic Acid

  • Placebo comparator
    Placebo

    10mL of 100mg/mL normal saline in addition to the standard care

    Drug: Placebo

Interventions

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.

  • DrugPlacebo

    10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.

06

What researchers measure

Primary outcomes

  1. acute post-op pain

    It will be assessed with VAS 0 to 10cm, with higher score indicating worse pain.

    Time frame: 24 hours to 72 hours postoperatively

Secondary outcomes

  1. opioid use

    Opioid use will be recorded on patients' medication diary

    Time frame: 1, 2, and 6-week post-surgery

  2. persistent pain

    It will be assessed with VAS 0 to 10cm, with higher score indicating worse pain.

    Time frame: 1, 2, and 6-week post-surgery

  3. unscheduled hand-related procedures

    clinic/emergency unit visits or any issue or events related to the condition that might lead participant to visit the emergency room, be seen by a doctor, or undergo any intervention more frequently than the usual visits

    Time frame: 1, 2, and 6-week post-surgery

  4. Patient reported function

    will be assessed using the disabilities of the arm, shoulder and hand questionnaire (DASH) score 0 to 100, with higher score indicating more disability.

    Time frame: 1, 2, and 6-week post-surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lameire DL, Noori A, Abbas A, Persitz J, Baltzer H, Collett E, Veillette C, Chan A, Paul R. The effect of topical TRanexamic Acid versus placebo on acute postoperative pain following Distal Radius fracture fixation: protocol for a randomised controlled trial at a quaternary care hand surgery centre - The TRADR study. BMJ Open. 2025 May 21;15(5):e095684. doi: 10.1136/bmjopen-2024-095684. PubMed 40398932 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Aug 13, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06384456
Responsible party
Ryan Paul (Dr., University Health Network, Toronto) — Principal investigator
First posted
Apr 25, 2024
Start date
Aug 13, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 4, 2026

Study contacts

Ryan Paul
Contact
jhanna.bermudez@uhn.ca
416-603-5839

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion